Aligos Therapeutics 

Aligos Therapeutics 

Yahoo Finance • 3 months ago

Aligos Secures $25M Upfront In Greater China HBV Deal; Stock Up

(RTTNews) - Aligos Therapeutics, Inc. (ALGS) announced it has received a $25 million upfront payment from Xiamen Amoytop Biotech Co., Ltd. under an exclusive license agreement for Pevifoscorvir sodium in Greater China. The therapy, aimed... Full story

Yahoo Finance • 4 months ago

Aligos Presents Promising Data For Pevifoscovir Sodium In Treating Hepatitis B

(RTTNews) - Aligos Therapeutics Inc. (ALGS), a clinical-stage biopharmaceutical company, on Wednesday presented positive data from ten presentations evaluating Pevifoscorvir sodium in treating chronic hepatitis B and other ongoing studies... Full story

Yahoo Finance • 4 months ago

Aligos Therapeutics Presents Positive Data at the EASL Congress 2026

Long-term follow up data from the Phase 1 study of pevifoscorvir sodium continues to suggest a reduction in the cccDNA reservoirData on the preclinical characteristics of the Aligos/Amoytop ASO program to be presented40% of HBeAg+ particip... Full story

Yahoo Finance • 5 months ago

Aligos Therapeutics Announces Ten Abstracts Accepted for Presentation at the EASL Congress 2026

SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral... Full story

Yahoo Finance • 5 months ago

Aligos Therapeutics GAAP EPS of -$2.21 beats by $0.04, revenue of $2.83M beats by $2.5M

* Aligos Therapeutics press release [https://seekingalpha.com/pr/20506698-aligos-therapeutics-reports-recent-business-progress-and-first-quarter-2026-financial-results] (ALGS [https://seekingalpha.com/symbol/ALGS]): Q1 GAAP EPS of -$2.21... Full story

Yahoo Finance • 5 months ago

Aligos Therapeutics Enters into Exclusive License Deal with Xiamen Amoytop Biotech Co., Ltd. to Develop and Commercialize Pevifoscorvir Sodium in Greater China for Chronic Hepatitis B Virus Infection

Aligos to receive an upfront payment of $25M USDUp to $420M USD in clinical, regulatory, and sales milestones along with tiered, high single-digit royaltiesAmoytop to fund its development program in Greater ChinaAmoytop is a leading Chines... Full story

Yahoo Finance • 7 months ago

Aligos Reports FY25 Results, Highlights Progress Across Liver And Viral Disease Pipeline

(RTTNews) - Aligos Therapeutics, Inc. (ALGS) has reported recent business progress and outlined continued advancement across its pipeline of drug candidates purpose-built for liver and viral diseases. For the fourth quarter of 2025, the c... Full story

Yahoo Finance • 10 months ago

Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”, “Company”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapie... Full story

Yahoo Finance • 11 months ago

Aligos Therapeutics to Announce 3rd Quarter 2025 Financial Results on November 6, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral dis... Full story

Yahoo Finance • 11 months ago

Aligos Therapeutics Receives USAN Council Approval for pevifoscorvir sodium as Nonproprietary Name for ALG-000184

SOUTH SAN FRANCISCO, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral... Full story

Yahoo Finance • 11 months ago

Aligos Therapeutics to Present at the H.C. Wainwright Liver Disease Conference

SOUTH SAN FRANCISCO, Calif., Oct. 14, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral... Full story

Yahoo Finance • 12 months ago

Aligos Therapeutics Announces Eight Abstracts Accepted at The Liver Meeting® 2025

SOUTH SAN FRANCISCO, Calif., Oct. 07, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral... Full story

Yahoo Finance • last year

Aligos Therapeutics Announces Six Preclinical Presentations at the 2025 International HBV Meeting

SOUTH SAN FRANCISCO, Calif., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and vira... Full story

Yahoo Finance • last year

Aligos Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral... Full story

Yahoo Finance • last year

Aligos begins dosing in phase 2 HBV drug study

SOUTH SAN FRANCISCO - Aligos Therapeutics, Inc. (NASDAQ:ALGS), a clinical-stage biotech company currently trading at $7.43 and identified as undervalued by InvestingPro analysts, has initiated dosing in the Phase 2 B-SUPREME study of its i... Full story

Yahoo Finance • last year

Aligos Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results

SOUTH SAN FRANCISCO, Calif., Aug. 06, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and... Full story

Yahoo Finance • last year

Aligos Therapeutics to Announce 2nd Quarter 2025 Financial Results on August 6, 2025

SOUTH SAN FRANCISCO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral dis... Full story

Yahoo Finance • last year

Aligos Therapeutics Appoints Kieron Wesson as Vice President, Head of Chemistry Manufacturing Controls (CMC)

SOUTH SAN FRANCISCO, Calif., June 18, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS) a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral... Full story

Yahoo Finance • 2 years ago

Aligos Therapeutics Presents Positive Data at APASL 2025

SOUTH SAN FRANCISCO, Calif., March 26, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liv... Full story

Yahoo Finance • 2 years ago

Aligos Therapeutics to Announce 4th Quarter 2024 Financial Results on March 10, 2025

SOUTH SAN FRANCISCO, Calif., March 03, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biotechnology company focused on improving patient outcomes through best-in-class therapies for liver and viral di... Full story